Member Info for jdt1990

Don't forget those options are also tied to SP and revenue targets. AS is incentivised to make this business a success! Unlike a lot of the bandits that run lifestyle companies on AIM.

DOH I think there's also sadly been a new influx of "have a go traders" since the pandemic began. People trying to earn a few extra quid (who can blame them) but either overleveraging themselves on spreadbets or overexposing them directly to make a quick buck.
Having seen the like of NCYT and SNG do 100%+ in a day, they believed that would happen here and are underwater and overexposed. To quote Chengdo, "those are the people I feel sorry for" and those are the ones here calling for AS's head on a stake.

Just for starters from the 18th Aug RNS
"In December 2018, Avacta and LG Chem entered into a multi-target therapeutics development agreement to develop Affimer® therapeutics in several disease areas potentially worth over $300m to Avacta. The companies have today agreed to expand this drug development partnership to include Avacta's Affimer XTTM technology, which can be used to control the time a drug spends in the circulation."
Daewoong
AVA6000
BAMS
ELISA
£40m on balance sheet from placing.

The point is the valuation should never have been based on the LFT. It was undervalued pre Covid due to limitations in developing the above quickly and effectively without funding. The placing that so many cried about actually unlocked the progress on all these. The raise has more than underpinned the case for a £300m mkt cap without the LFT, sadly the Co is riddled with Covid rainbow chasers in and out on that news alone!

I suspect that will very much be the case AgentB.....AS taking the stick for govts changing the goalpost!

Its a very good point AgentB and another reason AVCT/Affimers maybe don't get the credit they deserve from a bottom line perspective. Okay we haven't been selling millions of LFT's but every other use case we have had for Affimers, be that deepverge, BAMS on sale for research purposes etc. All these partnerships have been "commercially sensitive". So nobody can put a definitive revenue stream on paper.....I feel there could be a stark realisation when accounts are published that revenues have been slowly growing behind the scenes.

The govt are clearly wanting to make this as easy for themselves as possible. The questions will now be do you have a swab based LFT (a method already cleared by them clearly if innova are already receiving orders) and what is the price point / S&S. Avct can join that queue and Affimers hopefully put our test at the top of the S&S numbers.
Not messing around trying to have them approve an unproved collection method.
"the customer is always right" so they say. AS has realised this and we're now joining the race with what is hopefully superior tech in Affirmers which AVCT hold the full IP to, not a unique/superior device to house them in.
I like it

bump

its a good point mowzer and the big thing I got from this mornings RNS is that we are now embarking on a path to market that has already been trodden and proven to work by innova, surely that is a path of much less resistance with the govt. So long as it has superior S&S to innova!

Bump - Halleluiah someone gets it.
I was really pleased to see this morning AVCT had realised what they needed to do to get govt money in the door and capitalise on an opportunity. It wasn't to keep trying to only perfect the salifa LFT, it was to get a simpler, standard format nasal swab test out into the market.

Spot on - as long as the sampling method is not a brain tickler, people wont care how you collect it. What they will care about is that they are cheap, reliable and provide the necessary people with the ammo to put in place a testing programme that will allow a return to some form of "normality".
Nasal swab is just another string to the bow, not a replacement.

Gman I think you're right. I don't think this is the end of the road for saliva, but my guess is that someone with a big order in the wings isn't quite happy with the saliva test in its current form. Cue addition of a nasal swab to the mix.

tkevin - sadly you've uncovered yourself and your intentions with this comment "The point was the affimer test was never going to work"
THE AFFIMERS ARE THE BIT THAT DOES WORK AND THAT IS AVCTs IP......it's the form the test comes in (saliva/swab/breath whatever) that hasn't worked which is predominantly the job of Cytiva who have lead Avct down the garden path.
Course changed - onwards and upward

Funny how you've magically popped up here today and are an avid ODX poster though isnt it. I'll point you to a couple of RNS's
Expanded Partnership with Daewoong Pharmaceutical 29 Jul RNS
Expanded Partnership with LG Chem Life Sciences 18 Aug RNS
These partnerships are nothing to do with a Covid LFT, they are to do with the potential application of Affimers in various settings, to which AVCT hold sole rights to the IP. Would they be expanding them if this was dead duck tech?
Add to that the below in the RNS which is what COvid investors are completely overlooking:
"Furthermore, we remain on track to submit the UK regulatory application, or CTA, for AVA6000 pro-doxorubicin before the end of the year to allow first-in-human trials of the pre|CISION chemotherapy platform at several clinical trial sites in the UK early in 2021."
What value do you put on chemo with reduced side effects?
That's why I invested here so forgive me for being bored of talking about the "LFT race"

JHolder go back to ODX - If you’re interested in or have experience in the biotech space, it should come as no surprise that biotech companies with little to no revenue can still be worth billions. Consider the most prominent 2017 biotech M&A deal when Gilead bought Kite Pharma for almost $12 billion. At the time of the deal, Kite was still loss-making, with over $600 million in accumulated deficit, but significantly, it also had a pipeline of CAR-T cell therapies, which treat cancer. Kite wasn’t necessarily an anomaly. Almost 80% of the constituent companies of the Nasdaq Biotech Index (NBI) companies have no earnings; over 150 companies representing over $250 billion in market capitalization. And, the average VC investment in biotech has more than doubled over the past decade, from $4.6 billion in 2005 to $12.9 billion in 2015 so with Ovid who knows what that could increase to in 2020. As institutional equity investors, it’s clear that this cannot be simply explained by the exuberance of investors. Rather, it’s meant to demonstrate that pipeline often justifies the value of a company.
So when you talk about revenues from the LFT - this company is not just about the LFT. Far from it. It is demonstrating the power of Affimers in the diagnostic space and pushing on with Prec}sion in the therapeutics space.
You need to do a bit more homework to understand pharma valuations and what this company is actually looking to do. The major pharma partnerships with Daewoong and Moderna on the therapeutics side more than justify the Mkt Cap here but sadly the share has been overrun by COvid rainbow chasers

"Folks" don't care what form the test comes in. They want a test that facilitates a way for them to go about their daily life in some resemblance to normality and isn't nasopharyngeal.
So as long as it has the right S&S and can be produced in mass, nasal or saliva doesn't matter to Joe Bloggs.
It only really matters here because clearly Cytiva have led us down the garden path and we should have done nasal from day 1. Hindsight is great but we've committed to the change, onwards and upwards.
Be good to discuss this once the trading brigade bu**er off.

Ah well at least you've got your pointless gloat out o the way early in the day MB.....and the point in that post was?
Back under your ODX rock

graveyard of green boxes today!

shut up jag - you wont be buying anything here, you never have and never will do

Spike - as a long term holder I'm not sure I feel that negative. Clearly something isn't right with the saliva LFT that has led to the Uturn in sampling method. We could guess all day at what that is but clearly Cytiva need to be held accountable for that!
What is promising (despite the SP today showing differently) is that we have changed course going for the swab test rather than still focusing 100% on a saliva test that will clearly take some additional time (or be binned full stop).
Should have done thee swab first clearly but hindsight is a brilliant thing.
If S&S is top notch in the swab puts us back on track for where we wanted to be.

Hard to disagree with that skivy. This I guess has been the issue with having the Affimer IP but needing third parties to provide the additional work to produce a commercial, scalable product. Looks like we have been led down the garden path by Cytiva which is very annoying. Hopefully BBI can now just get this expedited and done.